Xenon Pharmaceuticals (XENE) Held by Superinvestors
XENON PHARMACEUTICALS INC (XENE) is currently held by 2 superinvestors tracked by InsiderSet, with a combined reported market value of approximately $25.70M based on the latest available SEC Form 13F filings for the quarter ended June 30, 2026.
Duquesne Family Office Llc is currently the largest disclosed institutional shareholder of XENE tracked by InsiderSet, reporting ownership valued at approximately $14.40M in its June 30, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $8.58M, representing an estimated loss of -40.44% since the filing period.
The top 10 institutional shareholders tracked on this page collectively account for approximately 100% of the total disclosed XENE value among the investors covered in this analysis. Major shareholders include Duquesne Family Office Llc, Renaissance Technologies LLC, and several other long-term asset managers with concentrated positions in XENON PHARMACEUTICALS INC (XENE).
This page ranks the largest institutional XENE shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.
| Name | Investor/Manager | Portfolio % | Quantity | Reported Balance | Current Estimated Value | Gain/loss Since Filing | Estimated Portfolio Performance |
|---|---|---|---|---|---|---|---|
| Duquesne Family Office Llc | Stanley Druckenmiller | 0.33% | 238,600 | $14,402,000 | $8,577,670 | -$5,824,330 | -40.44% |
| Renaissance Technologies LLC | Jim Simons | 0.02% | 187,110 | $11,293,960 | $6,726,605 | -$4,567,355 | -40.44% |
Frequently asked questions about XENE
Who are the largest superinvestors holding XENE?
The largest superinvestors holding XENE in the latest SEC Form 13F filings include Duquesne Family Office Llc and Renaissance Technologies LLC. InsiderSet ranks these superinvestors by their latest reported XENE position.
What does the XENE superinvestors page include?
This page tracks XENE positions reported by a curated group of notable institutional investors and fund managers through SEC Form 13F. XENON PHARMACEUTICALS INC (XENE) on this page reflects disclosed 13F holdings among those superinvestors, not every institutional shareholder of the stock.
How many superinvestors hold XENE?
InsiderSet currently tracks 2 superinvestors reporting XENE holdings in the latest available 13F data. This is the curated set on this page, not the total number of institutions that own XENE.
How much XENE stock do superinvestors hold?
Superinvestors tracked by InsiderSet disclosed approximately $25.70M in XENE holdings for Q2 2026. This figure is reported 13F value as of the filing period, not necessarily today's market value, and it covers the curated superinvestors on this page rather than every institutional filer.
When were XENE superinvestor holdings last updated?
The latest XENE superinvestor holdings on InsiderSet are based on SEC Form 13F filings for the quarter ended June 30, 2026. Form 13F filings are generally reported after the quarter ends, so the holdings shown represent the latest publicly disclosed positions rather than real-time holdings.
Are superinvestor XENE holdings real-time?
No. Form 13F data is not real-time. It represents positions reported by these superinvestors as of the end of the reporting quarter. A superinvestor may have changed its XENE position after the reporting date.
Are superinvestors buying or selling XENE?
Buying and selling can be analyzed by comparing XENE positions across consecutive 13F reporting periods. InsiderSet's XENE Ownership Changes page shows institutions that increased, reduced, initiated, or exited positions based on reported 13F holdings. View XENE ownership changes.
How have superinvestor XENE holdings changed over time?
InsiderSet tracks XENE holdings among these superinvestors across multiple 13F reporting periods, so holder counts, reported value, and reported shares can be compared over time.